产前皮质类固醇在早期和晚期的胎儿生长限制
Valentina Tosto1, Carolina Scala1, Nicola Fratelli2
1Obstetrics and Gynecology Unit, IRCCS Istituto Giannina Gaslini, 16147 Genova, Italy.
Journal of clinical medicine
|July 29, 2025
概括
产前皮质类固醇有助于预防早产婴儿的并发症. 然而,它们对胎儿生长受限制的胎儿的影响尚不清楚,因此需要进一步研究最佳妊娠年龄.
科学领域:
- 产科和妇科 产科和妇科
- 新生儿科学 新生儿科学
- 药理学 药理学是指药理学的学科.
背景情况:
- 产前皮质类固醇 (ACS) 是用于早产的标准,以减少新生儿发病率和死亡率.
- 有关ACS在胎儿生长限制 (FGR) 的胎儿中对中性或有害影响存在担忧.
- 胎儿生长限制可能表明早产婴儿对ACS的脆弱性增加.
研究的目的:
- 评估目前关于外源性ACS在FGR复杂的怀孕中的影响的科学证据.
- 为了确定妊娠年龄是否会影响ACS在这个特定的产科群体中的安全性和有效性.
主要方法:
- 对现有的科学文献进行系统审查.
- 对研究的分析检查了在怀孕期间与FGR进行ACS的管理.
- 对暴露新生儿的短期和长期结果的评估.
主要成果:
- 目前关于FGR怀孕中ACS影响的证据是不确定的.
- 管理时的妊娠年龄 (早期与晚期早产) 是需要进一步评估的关键因素.
- 与非FGR早产婴儿相比,ACS在FGR胎儿中的潜在差异性影响.
结论:
- 在FGR怀孕中使用ACS作为标准护理需要仔细考虑,因为证据不确.
- 需要进一步的研究来澄清基于FGR的妊娠年龄的ACS的风险和益处.
- 在FGR怀孕中,个体化评估对于管理早产至关重要.
相关概念视频
Teratogenicity
2.8K
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
2.8K
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
397
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
397
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
203
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
203
Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics
440
Respiratory symptoms, such as congestion and cough, commonly accompany respiratory tract conditions. Various medications, such as antitussives, expectorants, and mucolytics, play crucial roles in providing relief.
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla. Benzonatate operates peripherally within the respiratory tract by...
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla. Benzonatate operates peripherally within the respiratory tract by...
440
COPD: Management Using Bronchodilators and Corticosteroids
314
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
314
Adrenergic Antagonists: ɑ and β-Receptor Blockers
611
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
611


